Teicoplanin in the treatment of gram-positive-bacterial endocarditis

Antimicrob Agents Chemother. 1989 Aug;33(8):1329-34. doi: 10.1128/AAC.33.8.1329.

Abstract

Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usually with 3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h. For some cases (staphylococcal and enterococcal endocarditis), the dosage was 8 to 14.4 mg/kg per day and/or other antibiotics were given. The mean duration was 48.2 days (range, 23 to 130 days). Of 23 patients, 21 (91.3%) had negative cultures or were cured. A total of 18 patients were treated with teicoplanin alone; of these, 4 had surgery, and all (except 2 who relapsed) were cured. Teicoplanin was combined with one or more antibiotics in five cases; in all cases appropriate cultures were negative, but three patients died during therapy or follow-up. Mild renal impairment was seen in two patients; both were receiving teicoplanin in combination with an aminoglycoside. We conclude that intravenous teicoplanin administered once a day at doses of 7 to 14 mg/kg per day is well tolerated, easy to administer, and may represent an efficacious therapy for gram-positive-bacterial endocarditis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Enterococcus faecalis
  • Female
  • Glycopeptides / pharmacokinetics
  • Glycopeptides / therapeutic use
  • Gram-Positive Bacteria
  • Humans
  • Male
  • Middle Aged
  • Staphylococcus aureus
  • Streptococcus
  • Teicoplanin
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Glycopeptides
  • Teicoplanin